3 Biotech Millionaire-Makers

Small investments can create life-changing wealth...‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

SPONSORED 2021: The Year of Stockflation? $11.2 TRILLION is about to unleash the biggest force to ever hit the market... But three new initial public offerings could reap the fastest gains... Get the Details Here Editor's Note: Below, Contributing Analyst Jody Chudley discusses three early superstars of the biotech sector.. Just a small investment into one of these three stocks could have created life-changing wealth. Chief Income Strategist Marc Lichtenfeld wants to help you find tomorrow's best biotech stocks today. That's why he's currently offering a second year of his biotech research service, Lightning Trend Trader, for free to anyone who joins him today. Click here to learn more. - Mable Buchanan, Managing Editor BIOTECH INVESTING Why It Pays to Invest in the Biotech Sector Jody Chudley, Contributing Analyst, The Oxford Club Even in a widely diversified portfolio, just one good biotech stock selection can make a major difference. Since it launched roughly 40 years ago, as an industry, biotechnology has created incredible wealth for investors. With innovation moving so fast and with so many chronic diseases to tackle, the next four decades will be no different. In fact, I think the next four decades will be even better for biotech investors... What I especially love about the sector is that you don't need to invest much money in any stock to score portfolio-changing returns. Just look at what $1,000 invested into each of these three pioneers of the biotech sector has turned into for early shareholders... Biogen (Nasdaq: BIIB) was founded in 1978 by a small group of visionary scientists in Geneva, Switzerland. Two years later, founding member Walter Gilbert, Ph.D., won a Nobel Prize in chemistry for his work with DNA sequencing. The company went public in 1983. Investors who bought just $1,000 worth of Biogen shares as late as the early 1990s hit the mother lode. By 2015, that early Biogen investment had turned into more than $1 million. A $10,000 Biogen investment over the same period of time became a staggering $10 million. Even small investments produced life-changing wealth. Biogen's stock soared while the company discovered, developed and delivered treatments for neurological diseases for patients worldwide. Amgen (Nasdaq: AMGN) was founded at nearly the same time in 1980. It, too, went public in 1983. On the back of a groundbreaking gene discovery, Amgen developed the drug Epogen, a treatment for anemia associated with chronic renal failure. Epogen would go on to become one of the bestselling drugs of all time. SPONSORED FREEBIE! ($99 Value) Former CBOE pro Bryan Bottarelli is giving away a $99-value gift to those who view his FREE Win-Both-Ways Trade demonstration today. Amgen followed the Epogen success up with a white blood cell-boosting treatment called Neupogen, another big moneymaker. Amgen's stock chart looks remarkably similar to Biogen's. An early $1,000 purchase of Amgen shares is now worth more than $700,000. A $10,000 Amgen investment, meanwhile, has turned into more than $7.3 million. Again, investors who risked just a sliver of their portfolios saw life-changing wealth created by just this stock. Gilead Sciences (Nasdaq: GILD) was founded in 1987 under the name Oligogen. The company went public in 1992. Gilead's wealth creation for its shareholders has come on the back of several blockbuster infectious disease treatments. The company is responsible for several game-changing HIV treatments, including Truvada and the hepatitis C drug Sovaldi. A $1,000 early investment in Gilead shares was worth more than $350,000 by 2015. Anyone who put $10,000 to work in these shares was sitting on more than $3.5 million over the same period of time. Like Amgen and Biogen, Gilead has literally been a millionaire-maker. These three stocks haven't just helped investors grow their portfolios. They have single-handedly made investors' portfolios. Just $1,000 invested in any of these stocks would have been life changing. Today, the next big biotech winners are currently at the stage where these three companies were a few decades ago. Wouldn't it be fun to invest just a tiny fraction of your portfolio and end up owning the next one of these? Finding those big winners isn't easy, but with expert guidance, it is possible. And to make a huge difference to your wealth, you need to find only a single one. Click here to learn how you could find tomorrow's next top biotechs by joining Marc in Lightning Trend Trader. Good investing, Jody Leave a Comment MORE FROM WEALTHY RETIREMENT Does Pfizer's COVID-19 Vaccine Secure Its Dividend? Why Equally Weighted Index Funds Outperform Why Phase 2 Trials Are Important to Investors (and Why I'm Enrolled in One) Facebook Twitter Email Share SPONSORED You are receiving this email because you subscribed to Wealthy Retirement. Wealthy Retirement is published by The Oxford Club. Questions? Check out our FAQs. Trying to reach us? Contact us here. Please do not reply to this email as it goes to an unmonitored inbox. Privacy Policy | Whitelist Wealthy Retirement | Unsubscribe © 2021 The Oxford Club, LLC All Rights Reserved The Oxford Club | 105 West Monument Street | Baltimore, MD 21201 North America: 1.800.589.3430 | International: +1.443.353.4334 | Fax: 1.410.329.1923 Oxfordclub.com The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by The Oxford Club should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of The Oxford Club, 105 W. Monument Street, Baltimore MD 21201.